The Europe molecular diagnostics market size is estimated to register a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of diabetes, chronic diseases, cardiovascular, and other uncommunicable diseases.
Molecular diagnostics refers to the techniques in which biological markers are analyzed and applied for diagnostic and treatment purposes of infectious diseases as well as chronic illness. Scientific testing by applying molecular biology helps to diagnose & monitor disorders, mitigate risk, identify patients-based treatments along with agricultural biosecurity to monitor crop disease and take corrective measures.
As per the Health Protection Report 2019, more than 447,694 new sexually transmitted infection (STI) diagnoses were reported in England. Out of these, Chlamydia cases constituted nearly 218,095, which was around 49% of all new STI diagnoses, gonorrhea cases were 56,259 representing around 13%, first episode genital warts were 57,318 cases representing around 13%, and genital herpes were 33,867 around 8%.
The COVID-19 outbreak, as an infectious disease, which was started in Wuhan (China) in December 2019 has become global pandemic in matter of few weeks. The COVID-19 pandemic had a positive impact on the molecular diagnostics market due to the usage of molecular diagnostic techniques for novel corona virus testing. The number of tests and sales of reagents got affected due to the lockdowns caused by the pandemic globally.
However, surge in demand for diagnostic kits for COVID-19 testing across the globe due to strict regulations such as mandatory use of testing for travelers using commercial flights present a key aspect for the market development. Regulatory authorities have formulated policies to speed up approval of diagnostic products in both developing and developed countries. Several competitors in the healthcare industry have invested a massive funding to develop rapid tests for the virus as it becomes a need of the hour, which is expected to lower the negative impact of the pandemic on their operational capabilities and sustain their revenues.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing infectious diseases and chronic illness such as cancer in developed and developing regions is anticipated to upsurge the market growth.
- Rising demand for molecular diagnostics to diagnose various cancer and genetic diseases is projected to propel the market growth in the coming years.
- Technological advancement and new products development by key market players to enhance the diagnostic methods and procedures are major factors for accelerating the market growth.
- Expensive diagnosis instruments and high maintenance cost involved in molecular diagnostics that can only be afforded by large hospitals and laboratories, which adversely impact the market. This is expected to hinder the market expansion.
- Lack of skilled workers and delaying in molecular diagnosis tests approvals from regulatory bodies in some developed countries are the main challenges hampering the market growth.
- Demand for companion diagnostics is growing as these devices assist the healthcare providers to make informed decisions for patient-based treatment using appropriate therapy. This is projected to boost the market.
Scope of Molecular Diagnostics Market Report
The report on the Europe molecular diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Europe Molecular Diagnostics Market -Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Reagents, Instruments, and Others), Test Locations (Self-test, Point of Care, and Central Laboratories), Technology (Isothermal Nucleic Acid Amplification Technology, PCR, Multiplex PCR, In Situ Hybridization, Chips & Microarrays, Mass Spectrometry, Transcription-mediated Amplification, and Sequencing), Applications (Microbiology, Cardiovascular Disease, Pharmacogenomics, Infectious Diseases, Neurological Disease, and Others)
The UK, Germany, Italy, France, the Netherlands, and Rest of Europe
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Dako, Bayer AG; Abbott Laboratories; Alere, Inc.; Hologic, Inc. (Gen probe); Danaher Corporation; Sysmex Corp.; Becton, Dickinson and Co.; Novartis AG; Johnson and Johnson; Qiagen N.V.; Cephid; Roche Diagnostics; and bioMérieux SA
Molecular Diagnostics Market Segment Insights
Reagents segment is projected to expand substantially
On the basis of products, the market is segmented into instrument, reagents, and others. The reagents segment is projected to expand substantially in the market in the coming years owing to technological advancement in the diagnostic process to examine multiple diseases. The commonly used reagents include salts, formamide, SDS, dextran, and sulphate or heparin, to perform in-situ hybridization assays. Thus, the increasing demand for usage of techniques comprising fluorescence in situ hybridization present another key factor boosting the growth of the reagents segment.
Central Laboratories segment is anticipated to propel the market growth
Based on test Locations, the Europe molecular diagnostic market is segmented into self-test, point of care, and central laboratories. The central laboratories segment is anticipated to propel the market growth during the forecast period owing to the increasing number of trained professionals, higher patient footfall, and advanced facilities of laboratory. Moreover, the expansion of multiple clinical laboratory assays and easy availability of the advanced assays to perform molecular diagnosis of various illnesses are expected to boost the segment growth in the coming years.
On the other hand, the point of care segment is expected to upsurge at a considerable CAGR during the forecast period. Factors such as increasing demand for quick diagnosis, as well as the availability of newly developed PoC technology to monitor treatment reactions in patients having cardiac problem, are some key factors for driving segment growth.
PCR segment is anticipated to register a substantial growth rate
In terms of technology, the market is categorized as isothermal nucleic acid amplification technology, PCR, multiplex PCR, in situ hybridization, chips & microarrays, mass spectrometry, transcription-mediated amplification, and sequencing. The PCR segment is anticipated to register a substantial growth rate during the forecast period owing to rising adoption of the test for detecting infectious diseases especially the COVID virus. Moreover, wide application of the technology in molecular diagnostics research and study present another key factor boosting the segment growth.
Infectious disease segment is expected to register a large market share
Based on applications, the Europe molecular diagnostics market is segregated as microbiology, cardiovascular disease, pharmacogenomics, infectious diseases, neurological disease, and others. The infectious disease segment is expected to register a large market share during the forecast period due to the rising cases of infectious disease including HIV and other flu or viral diseases.
Moreover, the improvement in diagnostics test for the detection of infectious disease is anticipated to boost the segment growth. Meanwhile, the cardiovascular disease segment is projected to hold a major share of the market in the coming years due to increasing prevalence of cardiac arrest and heart-related diseases especially in the developed countries. Increasing demand for early and efficient diagnosis for detection of heart disease is further projected to escalate the segment expansion.
Germany is projected to dominate the market
In terms of regions, the Europe molecular diagnostics market is classified as the UK, Germany, Italy, France, the Netherlands, and Rest of Europe. Germany is projected to dominate the market, expanding at a rapid pace during the forecast period owing to rise in adoption of technological advancements in diagnostic kits and extensive research studies in the field of molecular diagnostics.
The UK, being the second major country generating high market revenue, is expected to register a substantial growth rate in the market during the forecast period. The presence of well-developed healthcare infrastructure, increasing disposable income, and the rising awareness regarding the benefits for the early diagnosis of diseases including cancer and HIV especially in the UK and Germany are the key factors contributing towards the growth of the overall regional market.
The Europe molecular diagnostic market has been segmented on the basis of
- Point of Care
- Central Laboratories
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Multiplex PCR
- In Situ Hybridization
- Chips & Microarrays
- Mass Spectrometry
- Transcription-mediated Amplification
- Cardiovascular Disease
- Infectious Diseases
- Neurological Disease
- The UK
- The Netherlands
- Rest of Europe
- Bio-Rad Laboratories, Inc.
- Siemens Healthcare GmbH
- Dako, Bayer AG
- Abbott Laboratories
- Alere, Inc.
- Hologic, Inc. (Gen probe)
- Danaher Corporation
- Sysmex Corp.
- Becton, Dickinson and Co.
- Novartis AG
- Johnson and Johnson
- Qiagen N.V.
- Roche Diagnostics
- BioMérieux SA
Some of the key players competing in the Europe molecular diagnostics market are Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Dako, Bayer AG; Abbott Laboratories; Alere, Inc.; Hologic, Inc. (Gen probe); Danaher Corporation; Sysmex Corp.; Becton, Dickinson and Co.; Novartis AG; Johnson and Johnson; Qiagen N.V.; Cephid; Roche Diagnostics; bioMérieux SA.
These major players are implementing various marketing strategies, such as capital investments, merger & acquisitions, and new product development to enhance their market position in the regional competition. For instance, In May 2020, Stratos Genomics was acquired by Roche Diagnostics (Roche) keeping its target to progress the development of nanopore technology and give access to Stratos Genomics unique chemistry, Sequencing by Expansion.
On the other hand, ID PoC system was launched by Abbott Laboratories in March, 2020. Neisseria gonorrhea and Chlamydia trachomatis testing kits are two diagnostic methods offered by Roche for the treatment of two common sexually contagion diseases. The improved version of these rapid testing tools is further expected to fuel the overall market growth.